Status:
COMPLETED
Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Lead Sponsor:
Eli Lilly and Company
Conditions:
Malignant Pleural Mesotherioma
Eligibility:
All Genders
20-75 years
Phase:
PHASE1
PHASE2
Brief Summary
To investigate efficacy and safety of pemetrexed combined with cisplatin for chemo-naive patients with Malignant Pleural Mesothelioma.
Eligibility Criteria
Inclusion
- Inapplicable for radical operation
- Not received prior systemic chemotherapy
- Performance status: 0-1
Exclusion
- Having a history of sensitivity to platinum agent, folic acid or vitamin B12
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00251550
Start Date
October 1 2005
End Date
August 1 2006
Last Update
November 6 2007
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Aichi, Japan
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Ehime, Japan
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Fukuoka, Japan
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Hokkaido, Japan